Abstract: Compounds of formula (I): wherein R1 represents optionally substituted C4-12 alkyl, optionally substituted C2-6alkylaryl, or optionally substituted 5- or 6-membered aryl or heteroaryl; Z represents a bond, CH2, O, S, SO, SO2, NR4, OCR4R5, CR4R5O, or Z, R1 and Q together form an optionally substituted fused tricyclic group; Q represents an optionally substituted 5- or 6-membered aryl or heteroaryl ring; X represents COR3 or N(OR8)COR9; R2 represents SO2R10 or SO2NR10R11; R3 represents OR6NR6R7 or NR6OH; R4 and R5 each independently represents H, C1-6 alkyl or C1-4 alkylaryl; R6 and R7 each independently represents H, C1-6 alkyl, or C1-6 alkyl substituted with one or more heteroaryl groups, or R6 and R7 together with the nitrogen atom to which they are attached form a 5- or 6-membered ring which may optionally include 1 or more further heteroatoms selected from O, S and N; R8 and R9 each independently represents H or C1-6 alkyl; R10 and R11 each independently represents H or C1-6 alkyl; and and physiologic

Abstract: Compounds of formula (I): wherein R1 represents optionally substituted C4-12 alkyl, optionally substituted C2-6alkylaryl, or optionally substituted 5- or 6-membered aryl or heteroaryl; Z represents a bond, CH2, O, S, SO, SO2, NR4, OCR4R5, CR4R5O, or Z, R1 and Q together form an optionally substituted fused tricyclic group; Q represents an optionally substituted 5- or 6-membered aryl or heteroaryl ring; X represents COR3 or N(OR8)COR9; R2 represents SO2R10 or SO2NR10R11; R3 represents OR6, NR6R7 or NR6OH; R4 and R5 each independently represents H, C1-6 alkyl or C1-4 alkylaryl; R6 and R7 each independently represents H, C1-6 alkyl, or C1-6 alkyl substituted with one or more heteroaryl groups, or R6 and R7 together with the nitrogen atom to which they are attached form a 5- or 6-membered ring which may optionally include 1 or more further heteroatoms selected from O, S and N; R8 and R9 each independently represents H or C1-6 alkyl; R10 and R11 each independently represents H or C1-6 alkyl; and and physiolo

Abstract: This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a non-nucleotide compound, preferably a P2Y12 receptor antagonist compound, wherein said amount is effective to inhibit platelet aggregation. The compounds useful for this invention include compounds of general Formulae I and III-XII, or salts, hydrates, and solvates thereof. The present invention also provides novel compounds of Formulae I and III-XII.

Abstract: The present invention is directed to synthetic cytoskeletal active compounds that are related to natural Latrunculin A or Latrunculin B. The present invention is also directed to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The invention is additionally directed to a method of preventing or treating diseases or conditions associated with actin polymerization. In one embodiment of the invention, the method treats increased intraocular pressure, such as primary open-angle glaucoma. The method comprises administering to a subject a therapeutically effective amount of a cytoskeletal active compound of Formula I or II, wherein said amount is effective to influence the cytoskeleton, for example by inhibiting actin polymerization.

Abstract: The present invention relates to a label (20) for a blister pack. In particular, it relates to a label which makes it more difficult for a child to release a medicament from the blister pack without making it unduly difficult for the elderly or infirm to remove the medicament. We describe a medicament blister pack label comprising a first sheet having first and second faces and a second sheet (22) having first and second faces, wherein the first face of the second sheet and the second face of the first sheet are opposed and bonded together; wherein at least portions of the first face of the first sheet are provided with a permanent adhesive (24); and wherein the sheet includes lines of weakness (30) defining medicament release zones.

Abstract: A system for inserting viewer-specific advertising content comprises a viewer device. The viewer device identifies viewer characteristics regarding the viewer. Upon receipt of advertising content, the viewer device identifies advertisements matching the viewer characteristics. The viewer device inserts the advertisements matching the viewer characteristics into broadcast content.

Abstract: Compounds of formula (I): wherein: Q represents an optionally substituted 5- or 6-membered aryl or heteroaryl ring; X represents O, S, NR5 or CR6 R7; Y represents CHOH, CHSH, NOR8, CNR8 or CNOR8; Z represents a bond, CR10R11, O, S, SO, SO2, NR10, OCR10R11, CR10R11 O or Z, R4 and Q together form an optionally substituted fused tricyclic group; R1, R1?, R3 and R3? each independently represents H, C1-6 alkyl or C1-4 alkylaryl; R2 represents CO2R8, CONR5OR9 or NR5COR9; R4 represents optionally substituted 5- or 6-membered aryl or heteroaryl; R5 represents H or C1-3 alkyl; R6 and R7 each independently represents H, C1-3 alkyl or halo; R8 represents H or C1-2 alkyl; R9 represents H or C1-3 alkyl; R10 and R11 each independently represents H, C1-6 alkyl or C1-4 alkylaryl; and physiologically functional derivatives thereof, processes for their preparation, pharmaceutical formulations containing them and their use as inhibitors of matrix metalloproteinase enzymes (MMPs) are described.

Abstract: Methods, systems, and products are disclosed for providing video services. A request for programming information for an event is received. A pointer to programming information that is common to multiple instances of the event is retrieved. The common programming information is retrieved.

Abstract: This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a non-nucleotide compound, preferably a P2Y12 receptor antagonist compound, wherein said amount is effective to inhibit platelet aggregation. The compounds useful for this invention include compounds of general Formulae III, IIIa, and IIIb, or salts, hydrates, and solvates thereof. The present invention also provides novel compounds of Formulae IIIa and IIIb, which are potent and have a good oral bioavailability.

Abstract: This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a non-nucleotide pyrimidine-based compound, preferably a P2Y12 receptor antagonist compound, wherein said amount is effective to inhibit platelet aggregation. The compounds useful for this invention include compounds of general Formulae I and Ia-Ic, or tautomers, salts, hydrates, and solvates thereof. The present invention also provides novel compounds of Formulae I and Ia-Ic.

Abstract: The present invention is directed to a processes for the synthesis of trans isomer of 4,6-disubstituted-tetrahydro-furo, thieno, pyrrolo and cyclopenta-[3,4][1,3]dioxoles (Formula I). The process comprises the steps of: (a) obtaining a compound of Formula II, which is a mixture of cis and trans-diastereomers, and (b) chemically decomposing the compound of Formula II in a solution comprising a solvent and an acid that is a hydrogen donor or an electron pair acceptor, whereby the cis diastereomer is decomposed and the compound of Formula I is obtained. The compounds prepared by the present invention are useful in treating diseases or conditions associated with platelet aggregation and/or platelet activation.

Abstract: The present invention is directed to synthetic cytoskeletal active compounds that are related to natural Latrunculin A or Latrunculin B. The present invention is also directed to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The invention is additionally directed to a method of preventing or treating diseases or conditions associated with actin polymerization. In one embodiment of the invention, the method treats increased intraocular pressure, such as primary open-angle glaucoma. The method comprises administering to a subject a therapeutically effective amount of a cytoskeletal active compound of Formula I or II, wherein said amount is effective to influence the cytoskeleton, for example by inhibiting actin polymerization.

Abstract: A system for inserting viewer-specific advertising content comprises a viewer device. The viewer device identifies viewer characteristics regarding the viewer. Upon receipt of advertising content, the viewer device identifies advertisements matching the viewer characteristics. The viewer device inserts the advertisements matching the viewer characteristics into broadcast content.

Abstract: Set top boxes are provided with access to full EIT data streams without having to off-tune from one transport to another. If off-tuning is required, however, a locking mechanism substantially reduces or eliminates service interruption. Data in the additional EIT data streams in the non-home transports is reorganized to be sent by time rather than by service. EIT data is stored in the set top box in an architecture which significantly reduces the redundancy inherent in EIT data, allowing a full 7 days of EIT data to be stored in the set top box memory. The set top box of the present invention is backward compatible with conventional set top boxes.

Abstract: This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a non-nucleotide compound, preferably a P2Y12 receptor antagonist compound, wherein said amount is effective to inhibit platelet aggregation, preferably in a reversible manner. The compounds useful for this invention include compounds of general Formulae I and III-XII, or salts, hydrates, and solvates thereof. The present invention also provides novel compounds of Formulae I and III-XII.

Abstract: The present invention relates to methods for identifying individual trees having a superior phenotype and more particularly to molecular markers and/or quantitative trait loci (QTL) which can be used to identify individual trees having a superior phenotype. The molecular markers and/or QTL comprise restriction fragment length polymorphism pattern or PCR-fingerprint. The molecular markers and/or QTL can be used for the development of marker-assisted breeding, rapid assessment techniques or to identify orthologous functional genes by sequence homology in trees of different a genus and/or species. DNA markers are e.g. for fibre coarseness, microfibril angle, pulpstrength and yield, lignin content, pitch propensity and calcium accumulation determinants.

Abstract: The present invention relates to a novel method for the prediction of fiber length and the selection of superior trees using genetic marker loci. The method comprises comparing genotypic survey data to phenotypic data collected from the same trees used to create the genotypic survey and identifying particular genetic marker loci or quantitative trait loci (QTL's) that are associated with fiber length. The method allows superior trees to be identified, from both plantations and natural populations, and selected for in tree improvement breeding programs by genotyping with identified genetic marker loci.

Abstract: A method for identifying genetic markers for the viability of sperm following freezing, using genome scanning techniques is disclosed. In an embodiment of the invention, a method for identifying the presence or absence of genetic markers associated with viability of pig semen following cryopreservation comprises the steps of: obtaining nucleic acid from a pig, and identifying the presence or absence of one or more markers for semen viability. Preferably, the identification of markers involves amplified restriction fragment length polymorphism techniques.

Abstract: The present invention relates to a novel method for the prediction of fibre length and the rapid selection of superior trees for given pulp and paper product lines using a DNA probe. The method comprises the isolation of tree genomic DNA from a hybrid spruce live tissue source, hybridization of the spruce DNA probe to that genomic DNA and the densitometric assessment of the intensity of the hybridization pattern obtained. This determines the precise degree of genetic admixing (or introgression) of the two parent species within the hybrid population. Due to the linear relationship—in the hybrid spruce population examined—between degree of genetic introgression and fibre length (discovered in this method), the intensity of the DNA probe hybridization pattern can be used to directly, accurately and reproducibly predict the fibre length found (for a given tree age) within an individual hybrid spruce within the population.

Abstract: The present invention relates to a method of identifying tree lineage capable of expressing desired biological and/or biochemical phenotypes and method of producing such trees. It also relates to a method of identifying a genetic marker associated with a genetic locus conferring at least one enhanced property. Also it relates to a stand of clonal enhanced property trees produced by the method of the present invention, the genome of the trees containing the same genetic marker associated with the enhanced property relative to a value characteristic of the average of the genus. It relates also to a method of producing a family of trees wherein at least about half exhibit at least of enhanced property. The present invention also relates to a genetic map of QTLs of trees associated with enhanced properties. The present invention further relates to a genetic marker of fiber length of trees.